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Abstract
Background: Resection of peritoneal metastases has been shown to improve survival in patients
with abdominal metastatic disease from abdominal or extra abdominal malignancy. This study
evaluates the benefit of peritoneal metastatic resection in patients with malignant small bowel
obstruction and a past history of treated cancer.
Patients and methods: Patients undergoing laparotomy for resection of peritoneal metastases
from recurrence of previous cancer between 1992–2003 were reviewed retrospectively. Data
were collected about type of primary cancer, interval to recurrence, extent of the disease and
completeness of resection, morbidity and mortality and long-term survival.
Results: Between 1992 and 2003 there were 79 patients (median age 62, range 19–91) who had
laparotomy for small bowel obstruction due to recurrent cancer. The primary cancer was
colorectal (31), gynaecologic cancer (19), melanoma (16) and others (13). Overall, the rate of
complications was 35% and mortality was 10%. Median survival was 5 months; patients with history
of colorectal cancer had better survival than other cancer (median survival 7 months vs. 4 months;
p = 0.02). Multivariate analysis showed that the extent of recurrent disease was the only factor that
affected overall survival.
Conclusion: Laparotomy for small bowel obstruction is a worthwhile option for patients with
malignant small bowel obstruction. Although it is associated with significant morbidity and mortality
it offers a reasonable survival benefit in particular for patients with completely resectable disease.
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Background
Bowel obstruction in patients with history of cancer is
caused by recurrence of cancer in 50% of patients [1,2]. In
patients with previously treated colorectal cancer with cur-
ative intent 10% develop small bowel obstruction; half of
them are due to recurrence [2]. Small bowel obstruction
due to recurrent cancer is commonly caused by colorectal
cancer, ovarian malignancies, and malignant melanoma
[3-5]. Small bowel obstruction due to recurrent cancer
tends to happen earlier (within two years of the initial sur-
gery) than obstructions caused by band adhesions, which
have a median time of occurrence of five years after the
initial surgery [3].
Small bowel obstruction secondary to recurrent cancer
carries a grim outlook, however surgical intervention
offers better palliation to reduce symptoms and has been
shown to reduce obstruction recurrence rates [5].
Although it is associated with high morbidity and mortal-
ity rates, surgical intervention is generally recommended
as the best palliation in such patients [4].
Long-term survival is variable and contributing factors are
poorly identified. We conducted this study to assess fac-
tors that affect long-term survival, which may help in
prognostication and management of patients with meta-
static peritoneal disease.
Patients and methods
Auckland City Hospital database was searched for patients
who had small bowel resection for cancer recurrence after
previous cancer surgery during the period 1992–2003.
Patients were included regardless of primary cancer origin.
Data were collected by reviewing patients' files including
patient demographics, type of primary cancer, time from
first diagnosis of cancer to small bowel resection, overall
morbidity and mortality, and length of survival after
resection of small bowel obstruction and peritoneal
metastases.
Overall survival was calculated and univariate analysis
(using Pearson correlation test) was performed to corre-
late survival with primary diagnosis, interval to recurrence
and extent of peritoneal disease. Long rank test was used
to compare survival difference between different groups.
Multivariate analysis was performed using the Cox regres-
sion hazard model to specify factors that have impact on
overall survival. Statistics were performed using SPSS®
11.5 for Windows (SPSS Inc., Chicago).
Results
Between January 1992 and December 2003, 79 patients
(34 males, median age 62, age range 19–91) had laparot-
omy and resection of peritoneal metastases with or with-
out small bowel resection for peritoneal metastases from
intra or extra abdominal cancers (table 1). The most com-
mon cause was colorectal cancer followed by gynaeco-
logic cancers. Less common cancers were breast (5),
stomach (3), lung (1), prostate (2), and kidney (1). Dif-
fuse non resectable disease was found in 59 patients, 20
patients had limited and resectable disease, which was
completely removed. Overall complications rate was 35%
and mortality rate was 10%. Median overall survival was
5 months (figure 1).
Overall survival correlates with type of primary cancer and
extent of peritoneal metastases (p = 0.03) (Pearson corre-
lation test). Patients with primary diagnosis of colorectal
cancer tend to have less peritoneal disease burden and
better overall survival than other types of malignancies
(median 7 months vs. 4 months, p = 0.02) (Figure 2).
Cox regression model of multivariate analysis was used to
compare factors that affect overall survival; it showed that
among factors that can possibly influence survival, extent
of peritoneal disease is the only factor to have an impor-
tant impact on survival. Median survival for patients with
completely resectable disease was 17 months compared
with 4 months for unresectable disease (p = 0.002). Age,
primary diagnosis and time interval between primary
resection and recurrence showed no effect on survival (fig-
ure 3).
Discussion
This study is a retrospective review of 12 years experience
with malignant small bowel obstruction. We found that
the commonest cause of recurrent malignant small bowel
obstruction is colorectal cancer, followed by gynaecologic
Table 1: Survival by primary malignancy
Disease extent
Primary Number Median Age Resectable Diffuse Disease free interval (median in years) Median Survival (months)
Colorectal 31 62 11 20 1.5 7.4
Melanoma 16 51 6 10 5.0 4.4
Gynaecologic 19 58 0 19 1.5 3.7
Miscellaneous 13 67 1 12 1.5 3.5World Journal of Surgical Oncology 2007, 5:122 http://www.wjso.com/content/5/1/122
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cancers and malignant melanoma. Malignant melanoma
was the commonest extra abdominal malignancy result-
ing in small bowel obstruction; compared to other cancers
it has the longest interval between primary treatment and
recurrence (median 5 years). Surgery offered a median
survival of 7 months with the best results seen in patients
with a primary diagnosis of colorectal cancer, and those
with isolated intra abdominal metastases where complete
macroscopic clearance of the disease was possible. Multi-
variate analysis showed that the extent of recurrent disease
was the only factor that affected overall survival. Although
patients with colorectal cancer had better overall survival
this may reflect the fact that it is more likely than other
cancers to have completely resectable disease.
Operative mortality has been reported as significantly
high particularly in patients who present with cancer
recurrence causing acute small bowel obstruction, Walsh
et al reported 19% mortality rate [2], other studies
reported 24% 30-day mortality rates [3]. Very high death
rates of 67% were reported after emergency laparotomy.
Surgical intervention in emergency patients is associated
with a significant rate of complications; wound complica-
tions, intra abdominal sepsis and cardiopulmonary com-
plications are the most common postoperative
complications [3]. The reported overall complication rate
varies from 8% in patients with melanoma [1] to 44% in
gynaecologic malignancies [6]. Median overall survival
varies from 5–11 months [2,7,8]. The longest survival is
reported in patients with metastatic malignant melanoma
by Agrawal et al., [1] who described median survival of 15
months after complete resection with five year survival
rate of 38%. Malignant melanoma was associated with the
longest interval between the primary diagnosis and
appearance of peritoneal metastases. Patients with a pri-
mary diagnosis of colorectal cancer seem to have better
outcome than other cases, with overall survival up to two
years [7], however most patients have disease recurrence
with two years of resection of the primary colorectal can-
cer [6].
Currently there is no universally accepted method of fol-
low up abdominal imaging to detect recurrence in those
who had colorectal or ovarian cancer resection. Tumour
markers such as CEA for colorectal cancer and CA 125 for
ovarian cancer are useful tools, however that does not
accurately define the time of recurrence, nor quantify the
extent of peritoneal disease. CT scan and contrast
enhanced CT colonography are useful tools for detection
of recurrent colorectal and ovarian and other cancers
[5,9,10]. PET is a promising tool for early detection of
Survival by extent of disease Figure 3
Survival by extent of disease.
Overall survival for all patients: fraction of surviving patients  against months Figure 1
Overall survival for all patients: fraction of surviving patients 
against months.
Survival difference between colorectal and other cancers (log  rank test) Figure 2
Survival difference between colorectal and other cancers (log 
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recurrent intra abdominal cancer when tumour markers
are elevated in a symptomatic patient with no signs of
recurrence on CT imaging [9,11-14], however this modal-
ity is not yet widely available. Future availability of PET
may increase the rate of early detection of recurrent dis-
ease at stages when it is resectable.
Conclusion
Metastatic peritoneal recurrence should be suspected in
patients with a history of malignancy who present with
small bowel obstruction. Aggressive surgical management
is recommended in those who prove to have resectable
disease, however consideration of this intervention has to
be mindful of the high rates of morbidity and mortality.
Every effort should be made to pursue a conservative man-
agement in those with non resectable recurrence. Future
efforts should be directed towards development of strate-
gies for early detection of intra abdominal recurrence.
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